Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases

Hepatology. 2020 Feb;71(2):757-759. doi: 10.1002/hep.30904. Epub 2019 Oct 10.

Authors

Yoshitaka Arase^{1

2}, Kota Tsuruya¹, Shunji Hirose¹, Naoki Ogiwara^{1

2}, Masashi Yokota^{1

2}, Kazuya Anzai^{1

3}, Ryuzo Deguchi^{1

2}, Koichi Shiraishi^{1

4}, Takayuki Shirai^{1

2}, Tatehiro Kagawa¹

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
² Division of Gastroenterology and Hepatology, Tokai University Oiso Hospital, Kanagawa, Japan.
³ Division of Gastroenterology and Hepatology, Tokai University Hachioji Hospital, Tokyo, Japan.
⁴ Division of Gastroenterology and Hepatology, Tokai University Tokyo Hospital, Tokyo, Japan.

No abstract available

MeSH terms

Aged
Autoimmune Diseases / complications*
Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / therapeutic use*
Denosumab / administration & dosage*
Denosumab / adverse effects
Female
Humans
Liver Diseases / complications*
Liver Diseases / immunology*
Middle Aged
Osteoporosis / etiology*
Time Factors
Treatment Outcome

Substances

Bone Density Conservation Agents
Denosumab